Literature DB >> 9716101

Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans.

H Valdimarsson1, M Stefansson, T Vikingsdottir, G J Arason, C Koch, S Thiel, J C Jensenius.   

Abstract

Mannan-binding lectin (MBL, previously named mannan-binding protein, MBP) is a serum collectin, which activates complement upon binding to microbial carbohydrates. This results in opsonization of the microorganisms as well as direct complement-mediated killing. Clinical evidence indicates that MBL has an important role in the innate immune defence against various pathogens. Genetically determined MBL deficiency is associated with increased susceptibility to infections. We have infused two MBL-deficient individuals with clinical grade MBL, purified from pooled donor plasma, in doses sufficient to attain normal concentration of MBL in serum. This resulted in normalization of complement-mediated opsonization. An initial rapid decrease in the serum concentration of MBL was followed by a slower decline with an estimated half-life of about 6 days. No adverse effects were observed and anti-MBL antibodies could not be detected following several MBL infusions. One of the two MBL recipient, a two-year-old girl, who had been suffering from repeated infections from the age of 4 months, was given a total of six MBL infusions. She has subsequently remained healthy for more than three years.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716101     DOI: 10.1046/j.1365-3083.1998.00396.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  20 in total

1.  Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition.

Authors:  O Neth; D L Jack; A W Dodds; H Holzel; N J Klein; M W Turner
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Mannose-binding lectin does not act as an acute-phase reactant in adults with community-acquired pneumococcal pneumonia.

Authors:  M Perez-Castellano; M Peñaranda; A Payeras; J Milà; M Riera; J Vidal; F Pujalte; A Pareja; C Villalonga; N Matamoros
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

3.  The binding of MBL to common bacteria in infectious diseases of children.

Authors:  Shi-qiang Shang; Guo-xian Chen; Jie Shen; Xiao-hong Yu; Ke-Yi Wang
Journal:  J Zhejiang Univ Sci B       Date:  2005-01       Impact factor: 3.066

4.  Role for mannose binding lectin in the prevention of Mycoplasma infection.

Authors:  Renata M J Hamvas; Marina Johnson; Arine M Vlieger; Clare Ling; Andrea Sherriff; Angela Wade; Nigel J Klein; Malcolm W Turner; A David B Webster
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Recombinant form of human wild type mannan-binding lectin (MBL/A) but not its structural variant (MBL/C) promotes phagocytosis of zymosan by activating complement.

Authors:  Rema Rajagopalan; Takazvida Nyaundi; Veena P Salvi; Nenoo Rawal
Journal:  Mol Immunol       Date:  2010-06-25       Impact factor: 4.407

6.  Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS.

Authors:  Kumud K Singh; Satyanarayana Nathamu; Anthony Adame; Tara U Alire; Wilmar Dumaop; Ben Gouaux; David J Moore; Eliezer Masliah
Journal:  Neurobehav HIV Med       Date:  2011-05-01

7.  An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children.

Authors:  Kumud K Singh; Alexis Lieser; Ping K Ruan; Terry Fenton; Stephen A Spector
Journal:  J Allergy Clin Immunol       Date:  2008-07       Impact factor: 10.793

8.  Genetic variation and cerebrospinal fluid levels of mannose binding lectin in pneumococcal meningitis patients.

Authors:  Matthijs C Brouwer; Frank Baas; Arie van der Ende; Diederik van de Beek
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Defective activities, but not secretions, resulting from gene point mutations of human mannan-binding lectin.

Authors:  Ying Liu; Feng-Ling Liu; Zhi-Jun Bai; Na Zhao; Li-Yun Zhang; Xiao Lu; Zheng-Liang Chen
Journal:  Mol Med Rep       Date:  2012-02-06       Impact factor: 2.952

10.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.